ReviewTranslational research : the journal of laboratory and clinical medicine2017
Cardiovascular consequences of metabolic syndrome.
Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 307 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
307 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Effects of resistant starch consumption on anthropometric and serum parameters in adults with metabolic syndrome-related risks: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- Relationship between body mass index and cardiovascular metabolic multimorbidity: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Pooled it
- Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review.International journal of molecular sciences · 2024Pooled it
- Pooled it
- Effects ofFrontiers in pharmacology · 2022Pooled it
- Clinical practice guideline of the Interamerican Society of Cardiology on primary prevention of cardiovascular disease in women.Archivos de cardiologia de Mexico · 2022Guideline
- Trial
- Trial
- The effect of dietary approaches to stop hypertension (DASH) diet on fatty liver and cardiovascular risk factors in subjects with metabolic syndrome: a randomized controlled trial.BMC endocrine disorders · 2024Trial
- Associations of obesity phenotypes with weight change, cardiometabolic benefits, and type 2 diabetes incidence during a lifestyle intervention: results from the PREVIEW study.International journal of obesity (2005) · 2023Trial
- Sirtuin signalling governs calcium homeostasis and mitochondrial function in metabolic syndrome cardiomyocytes.Experimental physiology · 2026Article
- The Complex Interplay Between Dyslipidemic Subjects Living with Type 2 Diabetes and Metabolic Syndrome and Statin Treatment: A Reflection on Adherence and Persistence in the Real World.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Metabolic health, independent of body mass index, is associated with mortality risk in type 1 diabetes.Journal of diabetes investigation · 2026Article
- Relationship of ABO blood groups with metabolic syndrome and its metabolic abnormalities in a population in North Lahore.Pakistan journal of medical sciences · 2026Article
- Ceramides: A Biologically Attractive Lipid and Advances in Acquisition Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Gestational Diabetes and Postpartum Cardiovascular, Kidney, and Metabolic Disorders.JAMA network open · 2026Article
- Article
- Effects ofMolecules (Basel, Switzerland) · 2026Article
- Electro-Mechanical Cardiac Remodeling in Metabolic Syndrome: Association Between Frontal QRS-T Angle and Subclinical Left Ventricular Dysfunction Assessed by Four-Dimensional Echocardiography.Journal of clinical medicine · 2026Article
247 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The metabolic syndrome (MetS) is defined as the concurrence of obesity-associated cardiovascular risk factors including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, decreased HDL cholesterol, and/or hypertension. Earlier conceptualizations of the MetS focused on insulin resistance as a core feature, and it is clearly coincident with the above list of features. Each component of the MetS is an independent risk factor for cardiovascular disease and the combination of these risk factors elevates rates and severity of cardiovascular disease, related to a spectrum of cardiovascular conditions including microvascular dysfunction, coronary atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure. While advances in understanding the etiology and consequences of this complex disorder have been made, the underlying pathophysiological mechanisms remain incompletely understood, and it is unclear how these concurrent risk factors conspire to produce the variety of obesity-associated adverse cardiovascular diseases. In this review, we highlight current knowledge regarding the pathophysiological consequences of obesity and the MetS on cardiovascular function and disease, including considerations of potential physiological and molecular mechanisms that may contribute to these adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.